Here’s whether Insmed, Inc. (INSM) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bearish.
🔴
Bearish
Positives: RSI 40 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-7.34% over 10 days); 3-month momentum negative (-32.3%). Currently 54.0% off its 52-week high. Score: -4/7.
INSM is trading below its 200-day MA ($154.40) — a key warning sign the longer-term trend is under pressure. An RSI of 39.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +1.0% compares to +22.9% for SPY (trailed the market by 21.9%). The current 54.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $10,100 today
vs. S&P 500 (SPY) — same period trailed market by 21.9%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✗Above 200-day MA ($154.40)
✗Above 50-day MA ($124.64)
✓RSI(14) neutral zone (30–70) — currently 39.9
✓Positive return (+1.0%)
!Within 10% of period high (−54.0%)
Period Range $97.85
$90.39$212.75
RSI (14) 39.9
0 · OversoldOverbought · 100
Key Metrics
Price$97.85
Period Return+1.0%
Period High$212.75
Period Low$90.39
Drawdown−54.0%
MA-50$124.64
MA-200$154.40
RSI (14)39.9
Avg Volume (30d)4.3M
vs. SPYtrailed by 21.9%
Return Rank#699 of 1246
Trend Signals
Price is below the 200-day moving average ($154.40)
Price is below the 50-day moving average ($124.64)